---
figid: PMC8417127__fonc-11-720842-g002
figtitle: 'Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy'
organisms:
- Escherichia coli
- Mycobacterium tuberculosis
- Streptococcus pneumoniae
- Klebsiella pneumoniae
- Lactiplantibacillus plantarum
- Bacteroides fragilis
- Campylobacter jejuni
- Fusobacterium nucleatum
- Bifidobacterium longum
- Akkermansia muciniphila
- Lacticaseibacillus rhamnosus
- Lacticaseibacillus rhamnosus GG
- Clostridium butyricum
- Candidatus Arthromitus sp. SFB-mouse
- Ruminococcus gnavus
- Ligilactobacillus salivarius
- Prevotella copri
- Blautia obeum
- Alistipes putredinis
- gut metagenome
- metagenomes
- Candida pruni nom. inval.
- Saccharomyces cerevisiae UFMG A-905
- Homo sapiens
- Mus musculus
- Bos taurus
organisms_ner:
- Bos taurus
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8417127
filename: fonc-11-720842-g002.jpg
figlink: /pmc/articles/PMC8417127/figure/f2/
number: F2
caption: Gut dysbiosis regulates lung inflammation and immunity. (1) Gut dysbiosis
  causes damage to the intestinal mucosal barrier, invading gut bacteria and metabolites
  affect the host’s inflammation and immunity locally and systematically which in
  turn leads to the carcinogensis of lung cancer. Bile acid (BA) stimulates inflammatory
  markers such as IL-1β、IL-6 and IL-8 in the lung. (2) 12,13-diHOME decreases the
  number of regulatory T (Treg) cells in the lungs resulting in a reduced anti-inflammatory
  effect. (3) Bacteria-derived antigens activates TLR4 in the intestine immune cells,
  which increases the level of IL-1β in peripheral circulation that activates NF-κB
  pathway, leading to pulmonary inflammation. (4) SFB-induced gut Th17 cells are preferentially
  recruited to lung due to robust expression in the lung of CCL20. (5) Gut dysbiosis
  leads to a decrease in the expression of ICAM-1, which decreases the number of activated
  and effective CD8+ T cells in tumors.
papertitle: 'The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy.'
reftext: Xiangjun Liu, et al. Front Oncol. 2021;11:720842.
year: '2021'
doi: 10.3389/fonc.2021.720842
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: gut microbiota | lung cancer | immunotherapy | gut-lung axis | biomarker
automl_pathway: 0.957598
figid_alias: PMC8417127__F2
figtype: Figure
redirect_from: /figures/PMC8417127__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8417127__fonc-11-720842-g002.html
  '@type': Dataset
  description: Gut dysbiosis regulates lung inflammation and immunity. (1) Gut dysbiosis
    causes damage to the intestinal mucosal barrier, invading gut bacteria and metabolites
    affect the host’s inflammation and immunity locally and systematically which in
    turn leads to the carcinogensis of lung cancer. Bile acid (BA) stimulates inflammatory
    markers such as IL-1β、IL-6 and IL-8 in the lung. (2) 12,13-diHOME decreases the
    number of regulatory T (Treg) cells in the lungs resulting in a reduced anti-inflammatory
    effect. (3) Bacteria-derived antigens activates TLR4 in the intestine immune cells,
    which increases the level of IL-1β in peripheral circulation that activates NF-κB
    pathway, leading to pulmonary inflammation. (4) SFB-induced gut Th17 cells are
    preferentially recruited to lung due to robust expression in the lung of CCL20.
    (5) Gut dysbiosis leads to a decrease in the expression of ICAM-1, which decreases
    the number of activated and effective CD8+ T cells in tumors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CXCL8
  - IL6
  - IL17A
  - TNF
  - CCL20
  - CCR6
  - LOC505306
  - TARP
  - IL13
  - ICAM1
  - Cxcl15
  - Il6
  - Il17a
  - Tnf
  - Nfkb1
  - Ccl20
  - Ccr6
  - Trav6-3
  - ag
  - Il13
  - Icam1
  - ba
  - Gusb
  - NFKB1
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CD8A
  - CD8B
  - egr
  - Dif
  - dl
  - Rel
  - Tcr
  - Dr
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
---
